Xie Wei, Chen Peijue, Luo Lili
The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Front Immunol. 2025 Jul 11;16:1626721. doi: 10.3389/fimmu.2025.1626721. eCollection 2025.
Therapeutic strategies for neuropsychiatric systemic lupus erythematosus (NPSLE) primarily target underlying pathogenic mechanisms and typically include corticosteroids, immunosuppressants, anticoagulation, and adjunctive treatments. B-cell-targeted biologics are an emerging option for NPSLE. Although telitacicept is approved for systemic lupus erythematosus (SLE) treatment in China, evidence supporting its use in NPSLE remains limited. This case report presents a 20-year-old female diagnosed with NPSLE who exhibited psychotic symptoms as the predominant manifestation and was treated with telitacicept, corticosteroids, and immunosuppressants. During the treatment period, her psychiatric symptoms remained in remission without infections or adverse events. Her disease activity score (SLEDAI-2000) declined from 23 to 2.
神经精神性系统性红斑狼疮（NPSLE）的治疗策略主要针对潜在的致病机制，通常包括使用皮质类固醇、免疫抑制剂、抗凝剂及辅助治疗。靶向B细胞的生物制剂是NPSLE的一种新兴治疗选择。尽管泰它西普在中国已获批用于系统性红斑狼疮（SLE）治疗，但支持其用于NPSLE的证据仍然有限。本病例报告介绍了一名20岁女性，诊断为NPSLE，以精神症状为主要表现，接受了泰它西普、皮质类固醇和免疫抑制剂治疗。治疗期间，她的精神症状持续缓解，未发生感染或不良事件。她的疾病活动评分（SLEDAI-2000）从23降至2。
